INDOCO REMEDIES LTD.

Indoco Remedies Ltd. announced that its Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi, Himachal Pradesh, has received EU GMP certification from the German Health Authority (Berlin). The inspection was conducted from April 22 to April 27, 2026. This certification confirms that the facility adheres to the Good Manufacturing Practice requirements as outlined in the EC Directive. Ms. Aditi Panandikar, Managing Director, highlighted that this certification underscores the company's dedication to delivering high-quality products to patients worldwide. Indoco is a fully integrated pharmaceutical company with a strong global presence and multiple manufacturing facilities approved by various regulatory authorities, including USFDA and UK-MHRA.

Indoco Remedies Ltd. has completed the transfer of its Ophthalmic Division to Sunways (India) Private Limited as a going concern on a slump sale basis. This transfer, effective May 18, 2026, follows the Agreement to Transfer Business (ATB) and fulfills all conditions precedent. The Ophthalmic Division includes operations in India, Benin, Burkina Faso, Ivory Coast, Mali, Niger, Mauritania, Senegal, Cameroon, Congo, Gabon, Kenya, Botswana, Tanzania, Zambia, Zimbabwe, and Namibia.

Indoco Remedies Ltd. announced the demise of Dr. Anand Nadkarni (DIN : 06881461), a Non-Executive Director of the company, on Friday, May 15, 2026. The company acknowledged Dr. Nadkarni's contributions and expressed condolences to his family. Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 were enclosed.

Indoco Remedies Ltd. announced that its manufacturing facility for solid oral dosage form (Unit I) in Baddi has received EU GMP certification from the Malta Medicines Authority after an inspection conducted from January 29, 2026, to February 3, 2026. The certification confirms compliance with Good Manufacturing Practice requirements as per the EC Directive. This approval reflects Indoco's commitment to quality and adherence to global regulatory standards.

Indoco Remedies Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a dividend of ₹0.20 per equity share, subject to shareholder approval. For the year ended March 31, 2026, the company's revenue from operations stood at ₹1633.54 million.

Indoco Remedies Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a dividend of ₹0.20 per equity share, subject to shareholder approval. The company's revenue from operations for the year stood at ₹1633.54 million. The meeting, which commenced at 11:05 a.m., concluded at 12:30 p.m.

Indoco Remedies Ltd. announced the strategic transfer of its ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited. The Board approved this divestment, which Indoco Remedies states will allow it to sharpen its focus on core therapeutic areas with stronger potential. For Sunways, the transaction is expected to strengthen its ophthalmology platform by adding an established operating business and complementing its existing product portfolio and manufacturing capabilities. Sunways is a specialized pharmaceutical company focusing on ophthalmology and ENT formulations. Both companies' management highlighted the strategic benefits of the transaction for their respective businesses.

Indoco Remedies Ltd has approved the transfer of its ophthalmic business (Ophthalmic Division) to Sunways (India) Private Limited via a slump sale. The transaction covers territories in India and several African countries. The consideration for the sale is ₹110 Crores, subject to adjustments. For the financial year ended March 31, 2025, the Ophthalmic Division contributed ₹47.79 Crores to the company's standalone revenue, representing 3.2% of total continuing operations revenue. The buyer, Sunways (India) Private Limited, reported standalone revenue of ₹137.42 Crores for FY25 and is not a related party. The transaction is expected to be completed in approximately three months, subject to fulfillment of conditions precedent.

Indoco Remedies Ltd has announced that its Board of Directors will convene a meeting on Thursday, May 7, 2026. The primary agenda includes considering and approving the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Additionally, the Board will consider recommending a final dividend for the financial year ending March 31, 2026, if applicable. The trading window for designated persons and their immediate relatives remains closed until May 9, 2026, which is 48 hours after the declaration of the financial results.

Indoco Remedies Ltd announced that the U.S. Food and Drug Administration (U.S. FDA) completed a Pre-Approval Inspection at the Company's testing facility in Chhatrapati Sambaji Nagar (Aurangabad). The inspection was conducted from April 08, 2026, to April 10, 2026, and concluded with zero Form 483 observations. This positive outcome indicates the facility's compliance with regulatory standards, which is crucial for future product approvals and maintaining market access in the US.